JDRF's Kowalski Sees Hope in Bipartisan Support for Insulin Pricing Reform
September 26th 2019Aaron Kowalski, PhD, the new CEO of the JDRF, says in a discussion about insulin pricing that action is needed not only by Congress, but also by insulin makers, health plans, and the executive branch. The most important goal: ending a crosspayment scheme that many blame for potentially deadly price increases.
Read More
Renting Health vs Buying Cures: How New Financing Tools Can Boost Cancer Therapy Development
December 7th 2018Evidence-Based OncologyTM sat down with Andrew W. Lo, PhD, to discuss his proposals to increase investment in medical innovation and utilization by giving investors more ways to support both research organizations and individual patients.
Read More
As Trials Report Cardiovascular Outcomes Data, What About Microvascular Results?
December 18th 2017Evidence is more robust on kidney function but not sufficient to make drug decisions, one expert said. A whole separate trial, called CREDENCE, is examining renal function in patients taking canagliflozin.
Read More
UnitedHealthcare's Medtronic Deal Sparks Furor, but a Year Later, Innovation Continues
September 23rd 2017UnitedHealthcare has not released numbers on how many patients are affected by its exclusivity deal with Medtronic. While the initial press stories criticizing the transaction have died down, a JDRF initiative calls on insurers to preserve patient choice.
Read More
Latest GAO Report Disputes Criticism of Controversial Test Strip Program
December 13th 2016A recent report from the Government Accountability Office mostly concurs with CMS on a dispute over problems with the Medicare competitive bidding program, following an explosive study in Diabetes Care that found beneficiaries lost access to key supplies.
Read More
As Metformin Combinations Proliferate, Questions Arise About Value
September 21st 2016For some patients newly diagnosed with type 2 diabetes, skipping metformin monotherapy and going straight to fixed-dose combinations with a DPP-4 inhibitor or an SGLT2 inhibitor makes sense, evidence shows.
Read More
From Contrave Saga, Renewed Faith in Trials Built on Trust
September 19th 2015The decision by Cleveland Clinic's Steven Nissen, MD, to issue his own press release last spring after the cardiovascular outcomes trial was halted for Contrave turned plenty of heads in the pharmaceutical community. But Nissen and others involved in the saga see what happened with Orexigen as a one-time incident, not a flaw with the process for evaluating the safety of diabetes and obesity therapies.
Read More
Toujeo and Afrezza: New and Improved Insulins, Limited by FDA Labeling Constraints
May 19th 2015Two new insulins marketed by Sanofi offer improved options for patients: Toujeo is longer acting than its predecessor, Lantus. Afrezza, an inhaled insulin, is gaining praise from patients, if not from Wall Street.
Read More